10-K: Neurocrine Biosciences Reports Strong 2025 Sales, Pipeline Advances

Neurocrine Biosciences achieved significant revenue growth in 2025 driven by strong INGREZZA sales and the successful launch of CRENESSITY, while advancing a robust pipeline and navigating evolving regulatory landscapes.

Summary

• Total net product sales increased 21.6% to $2.83 billion in 2025, up from $2.33 billion in 2024 and $1.86 billion in 2023.
• INGREZZA net product sales reached $2.51 billion in 2025, a significant increase from $2.31 billion in 2024 and $1.84 billion in 2023, driven by record total prescriptions.
• CRENESITY, launched in December 2024, generated $301.2 million in net product sales for its first full year in 2025.
• The company initiated Phase 3 clinical programs for osavampator in Major Depressive Disorder (MDD) and direclidine in schizophrenia, with initial topline data expected in 2027 for both.
• A Phase 2 study for direclidine in bipolar mania was initiated in Q4 2025.
• Several early-stage programs advanced into Phase 1 or Phase 2 development, including next-generation VMAT2 inhibitors (NBI-1065890, NBI-1140675), a long-acting CRF-1 receptor antagonist peptide (NBIP-01435) for CAH, and a selective sodium channel inhibitor (NBI-921355) for epilepsy.
• The planned expansion of INGREZZA and CRENESITY sales teams, announced in October 2025 and expected to complete by Q1 2026, aims to boost market penetration and support future product launches.
• Neurocrine Biosciences qualified for the small biotech exception under the Medicare Drug Price Negotiation Program for INGREZZA, exempting it from selection until 2027 (for 2029 price applicability).
• The company completed a $300 million accelerated share repurchase program in February 2025 and authorized a new $500 million program in February 2025, repurchasing 1.5 million shares for $167.7 million in 2025.
• The Neurocrine Group Limited operating unit was sold to Immedica Pharma AB for $65.0 million in cash on January 21, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting strong commercial performance from key products and significant pipeline advancement. While regulatory scrutiny and competitive pressures are noted, the company's financial growth and strategic R&D investments suggest a favorable trajectory.

Positives

• Strong revenue growth in 2025, with total net product sales increasing by 21.6% to $2.83 billion.
• INGREZZA sales continued to grow, reaching $2.51 billion in 2025, driven by strong patient demand and record prescriptions.
• Successful first full-year launch of CRENESITY, generating $301.2 million in net product sales.
• Advancement of multiple late-stage pipeline candidates, including Phase 3 initiations for osavampator (MDD) and direclidine (schizophrenia).
• Expansion of early-stage pipeline with several compounds entering Phase 1 and Phase 2 development, demonstrating a robust R&D engine.
• INGREZZA qualified for the small biotech exception under the Medicare Drug Price Negotiation Program, providing an exemption from price negotiation until 2027 (for 2029 price applicability).
• Expanded formulary access for INGREZZA, covering approximately 70% of TD and Huntington's disease Medicare beneficiaries.
• Positive top-line data from the Phase 4 KINECT-PRO study for INGREZZA, showing clinically meaningful and sustained effects on TD symptoms and patient-reported outcomes.
• Positive data from the Phase 2 SAVITRI study for osavampator, showing statistically significant and clinically meaningful improvement in depression severity.
• Strategic sale of Neurocrine Group Limited for $65.0 million, streamlining operations.
• Authorization of a new $500 million share repurchase program, indicating confidence in financial health and commitment to shareholder returns.

Negatives

• INGREZZA net price was lower in 2025 due to new market access investments, partially offsetting sales growth.
• Phase 3 studies of valbenazine in schizophrenia and dyskinesia due to cerebral palsy (DCP), and a Phase 2 study of NBI-1070770 in MDD, did not meet their primary endpoints.
• A civil investigative demand was received from the U.S. Department of Justice (DOJ) in August 2025 regarding sales and marketing of INGREZZA.
• In September 2025, the FDA Office of Prescription Drug Promotion issued an untitled letter alleging certain claims in INGREZZA promotional material are misleading.
• Lower negotiated prices for competitor AUSTEDO/AUSTEDO XR under Medicare drug negotiation may increase competitive pressures on INGREZZA.
• The Inflation Reduction Act (IRA) and other healthcare reform measures are expected to result in more rigorous coverage criteria and lower reimbursement for prescription drugs, potentially impacting future revenues.
• The One Big Beautiful Bill Act (OBBBA) is anticipated to reduce the number of Americans with health insurance, potentially impacting patient access and sales.
• Increased R&D expenses in 2025 ($1,015.7 million) compared to 2024 ($731.1 million) and 2023 ($565.0 million), reflecting substantial investments that may not yield successful products.
• Unrealized loss on equity investments of $4.0 million in 2025, following a $37.1 million loss in 2024.

Risks

• Inability to successfully commercialize INGREZZA or CRENESSITY, or any future approved product candidates.
• Physicians and patients may not accept INGREZZA or CRENESSITY, or sales and marketing efforts may be ineffective, leading to insufficient revenue.
• Intense competition from academic institutions, government agencies, research institutions, and other biotechnology and pharmaceutical companies, including generic equivalents and alternative therapies.
• Government and third-party payors may impose sales and pharmaceutical pricing controls, or limit coverage and/or reimbursement for products, potentially reducing revenues and delaying profitability.
• Technological uncertainty in product candidate development, with a small number of programs ultimately resulting in commercially successful drugs.
• Clinical trials may be delayed for safety or other reasons, or fail to demonstrate safety and efficacy, preventing or delaying regulatory approval.
• Enacted healthcare reform, drug pricing measures (including the IRA), and other legislative initiatives could adversely affect the business.
• Difficulties in managing organizational growth, including recruiting and retaining qualified personnel, and expanding infrastructure (e.g., ERP system implementation).
• Challenges in transforming R&D strategies to include biologics development, requiring substantial investment and expertise, with potential for development or commercialization failure.
• Loss of key senior executives or inability to retain and recruit qualified scientists and other employees.
• Approved products or those of collaborators could be associated with side effects or adverse events, negatively impacting demand or regulatory approval.
• Dependence on a limited number of third-party suppliers for manufacturing, risking supply disruptions.
• Dependence on current and future collaborators for development and commercialization, with risks of disagreements, insufficient funding, or competitive product development.
• Lack of internal manufacturing capabilities, relying entirely on third-party manufacturers who may fail to meet standards or devote sufficient resources.
• Defaulting on obligations or violating terms of licenses for core technologies, drug leads, products, and product candidates, leading to loss of rights or damages.
• Concentration of customers, with four customers representing over 90% of total gross product sales, posing a risk if a significant customer is lost.
• Need for additional capital in the future, with no guarantee of availability on reasonable terms.
• Expected increase in expenses for the foreseeable future, with no assurance of sustained growth and profitability.
• Independent clinical investigators and contract research organizations may not be diligent, careful, timely, or may make mistakes in clinical trials.
• Ongoing regulatory obligations and continued review for approved products, with potential for labeling restrictions, post-marketing requirements, or enforcement actions (e.g., FDA untitled letter regarding INGREZZA promotion).
• Market opportunities for products and product candidates may be smaller than estimated due to underserved/underdiagnosed populations or incorrect coding.
• Operating results may vary significantly in future periods due to seasonality, timing of purchases, Medicare Part D changes, R&D objectives, geopolitical/macroeconomic developments, and other factors.
• Changes in tax laws or regulations (e.g., OBBBA, OECD Pillar Two framework) could adversely affect business, cash flows, financial condition, or results of operations.
• Volatility in common stock price due to various factors, including sales performance, clinical trial results, safety issues, regulatory developments, and analyst forecasts.
• Increased use of social media could lead to liability and harm to the business.
• Claims of wrongful use or disclosure of trade secrets from former employers.
• Changes in government agencies (FDA, USPTO) could hinder their ability to perform normal business functions, delaying product development and commercialization.
• Potential liability if a regulatory authority determines promotion of off-label uses.
• Compromise of information technology systems, those of third parties, or data, leading to operational interruptions, data breaches, reputational harm, and regulatory actions.
• Unfavorable geopolitical and macroeconomic developments (tariffs, trade barriers, conflicts) could adversely affect business and supply chain.
• Failure to obtain or maintain orphan drug designation or other regulatory exclusivity for some product candidates.
• Technologies used in research as well as drug targets selected may infringe the patents or violate the proprietary rights of third parties.
• Business operations may subject the company to disputes, claims, and lawsuits, which may be costly and time-consuming and could materially and adversely impact financial position and results of operations.
• Employees, independent contractors, principal investigators, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
• Potential product liability exposure far in excess of insurance coverage.
• Activities involve hazardous materials, with potential liability for any resulting contamination or injuries.
• Subject to stringent and changing obligations related to data privacy and information security, with actual or perceived failure to comply potentially having a material adverse effect on reputation, business, financial condition, or results of operations.

Future Outlook

The company expects to complete the expansion of INGREZZA and CRENESITY sales teams by the end of Q1 2026. Plans include filing an Investigational New Drug (IND) application and advancing NBIP-2118 into Phase 1 development in the first half of 2026. Initial topline data for osavampator Phase 3 (MDD) and direclidine Phase 3 (schizophrenia) are expected in 2027. The company aims to launch, on average, approximately one new medicine every two years and advance at least four new programs into Phase 1 and two programs into Phase 2 each year. Substantial investments in R&D personnel are anticipated to support expansion into biologics. Existing capital resources, anticipated INGREZZA and CRENESITY sales, and investment income are believed to be sufficient for funding requirements for at least the next 12 months.

Management Comments

• Our purpose: to relieve suffering for people with great needs.
• Key elements of our commercial strategy include maximizing the opportunities in INGREZZA and CRENESITY through consistent and effective commercial execution, continued development of valbenazine as the best-in-class treatment for new patient populations, and to lead the evolving understanding of vesicular monoamine transporter 2 (VMAT2) biology and its role in disease.
• We believe these investments in commercial capabilities will translate into sustained revenue growth and shareholder value, as we drive current product performance and prepare to bring new therapies to market.
• Our strategy is to maintain a balanced portfolio by stage of development and across our therapeutic areas of interest... thereby positioning Neurocrine Biosciences to deliver a steady cadence of innovative medicines for years to come.
• By harnessing both novel validated mechanisms and our proprietary platforms, we aim to launch, on average, approximately one new medicine every two years, driving long-term value for patients and shareholders.
• Our confidence in this approach [CRF-2 agonist for obesity] is bolstered by our internal know-how of over 30 years studying CRF biology and the success of our first CRF program in CAH.
• Our clinical development pipeline is both deep and differentiated, comprising multiple late-stage opportunities with near-term registration potential and a wide base of early-stage programs designed to drive growth into the next decade.
• We believe our pipelines breadth, scientific sophistication, and strategic alignment position us to deliver sustainable innovation and therapeutic breakthroughs to relieve suffering for people with great needs.
• Management believes that an adequate provision has been made for any adjustments that may result from tax examinations.

Industry Context

StockSavvy.ai notes that Neurocrine Biosciences operates in a highly competitive and rapidly evolving biopharmaceutical landscape, particularly in neuroscience. The company's strategy to diversify its pipeline across prevalent CNS disorders and rare/orphan diseases, coupled with its expansion into biologics and gene therapies, aligns with broader industry trends seeking novel modalities and addressing unmet medical needs. The successful launch of CRENESITY, a first-in-class treatment for CAH, positions it favorably in the rare disease market, while the continued growth of INGREZZA demonstrates strong commercial execution in established indications. However, the industry faces increasing pressure from government and third-party payors regarding drug pricing and reimbursement, as evidenced by the Inflation Reduction Act and the selection of competitor AUSTEDO for Medicare price negotiation, which could impact market dynamics for INGREZZA. The company's proactive sales team expansion and robust R&D investment are critical for maintaining competitiveness against numerous established and emerging players.

Comparison to Industry Standards

• Neurocrine Biosciences' INGREZZA competes directly with Teva Pharmaceuticals Industries' AUSTEDO (deutetrabenazine) for TD and chorea associated with Huntington's disease. AUSTEDO XR, a once-daily formulation, was introduced in February 2023, potentially offering a convenience advantage. AUSTEDO and AUSTEDO XR were selected for the Medicare drug negotiation program in 2025 (for 2027 price applicability), resulting in a lower negotiated maximum fair price (MFP). This could intensify pricing pressure on INGREZZA, which, while currently exempt as a small biotech until 2027 (for 2029 price applicability), will face similar scrutiny.
• CRENESITY, as a first-in-class FDA-approved treatment for classic CAH, competes with high-dose corticosteroid monotherapy, the long-standing standard of care. Its novel mechanism offers a differentiated approach in a market with over two dozen companies manufacturing steroid-based products. The 7 years of orphan drug exclusivity granted to CRENESITY provides a significant competitive advantage against direct competitors for the same indication.
• In the broader psychiatry pipeline, osavampator for MDD and direclidine for schizophrenia are targeting large markets with significant unmet needs, where current antipsychotics and antidepressants often have limitations or side effects. Direclidine's selective M4 receptor agonism represents a novel mechanism compared to dopamine-modulating antipsychotics, potentially offering improved safety and tolerability, similar to how other novel mechanisms are sought in the industry to overcome existing drug limitations.
• The company's goal to launch approximately one new medicine every two years, coupled with advancing at least four new Phase 1 and two new Phase 2 programs annually, reflects an aggressive R&D strategy comparable to leading biopharmaceutical innovators.

Management Changes

Corporate Governance

Legal Proceedings

• Zydus Lifesciences Global FZE filed an abbreviated new drug application (ANDA) with the FDA in March 2025, seeking approval for a generic version of INGREZZA SPRINKLE, alleging patent invalidity/non-infringement.
• Neurocrine Biosciences filed suit in the U.S. District Court for the District of Delaware in April 2025 against Zydus, alleging patent infringement and seeking to prevent generic INGREZZA SPRINKLE sales.
• A similar suit was filed in the U.S. District Court for the District of New Jersey in April 2025 against Zydus, which was subsequently dismissed in favor of the Delaware proceeding.
• Received a civil investigative demand from the U.S. Department of Justice (DOJ) in August 2025 requesting documents and information related to sales and marketing of INGREZZA. The company is cooperating.
• Received an untitled letter from the FDA Office of Prescription Drug Promotion in September 2025, alleging certain claims in INGREZZA promotional material are misleading.

Related Party Transactions

• Jude Onyia, Ph.D., Chief Scientific Officer of Neurocrine Biosciences, was appointed to Voyager Therapeutics, Inc.'s board of directors as part of the 2023 Voyager Agreement. Neurocrine's equity investment in Voyager became subject to the equity method of accounting, and Voyager became a related party, after the purchase of 2023 Voyager Shares, bringing total ownership to approximately 19.9% of Voyager's voting stock.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, increased net income and EPS, share repurchase programs, and a robust pipeline. Potential negative impact from increased R&D expenses, regulatory scrutiny (DOJ, FDA letter), and competitive pressures.
• Employees: Positive impact from increased headcount, planned sales team expansion, competitive compensation and benefits, and talent development programs. Potential retention challenges due to rapid growth and perceived impact on corporate culture.
• Customers (Patients/Prescribers): Positive impact from new FDA-approved treatments (CRENESITY) and continued development of therapies for unmet needs. Potential negative impact from drug pricing pressures and changes in reimbursement policies affecting access or out-of-pocket costs.
• Suppliers/Manufacturers: Continued reliance on third-party manufacturers and suppliers, indicating ongoing business for these partners. Potential for supply disruptions if manufacturers face difficulties.
• Creditors: Strong financial performance and cash flow from operations enhance creditworthiness.

Next Steps

• Complete the expansion of INGREZZA and CRENESITY sales teams by the end of Q1 2026.
• File an Investigational New Drug (IND) application and advance NBIP-2118 into Phase 1 development in the first half of 2026.
• Expect initial topline data for osavampator Phase 3 (MDD) and direclidine Phase 3 (schizophrenia) in 2027.
• Continue to advance at least four new programs into Phase 1 and two programs into Phase 2 each year.
• Continue making substantial investments in R&D personnel to support expansion into biologics.
• Cooperate with the U.S. Department of Justice's civil investigative demand regarding INGREZZA sales and marketing.
• Address the FDA Office of Prescription Drug Promotion's untitled letter regarding INGREZZA promotional material.
• Recognize the gain from the sale of Neurocrine Group Limited in Q1 2026.
• Monitor the impact of the Medicare Part D manufacturer discount program and potential future drug pricing regulations.

Key Dates

Recommendation

Neurocrine Biosciences demonstrates robust financial health with significant revenue and earnings growth driven by its flagship products, INGREZZA and the newly launched CRENESITY. The company's deep and diversified pipeline, with multiple late-stage programs and a strategic focus on biologics and gene therapies, positions it for sustained long-term growth. While regulatory challenges and competitive pressures exist, the company's proactive measures, including sales team expansion and share repurchase programs, underscore management's confidence. The strong operating cash flow and substantial cash reserves provide ample funding for future R&D and commercialization efforts, making it an attractive investment for growth-oriented portfolios.

Keywords

Neurocrine Biosciences, Biopharmaceutical, Neuroscience, Tardive Dyskinesia, Huntington's Disease, Congenital Adrenal Hyperplasia, INGREZZA, CRENESITY, Valbenazine, Crinecerfont, Drug Development, Clinical Trials, FDA Approval, SEC Filing, 10-K, Pharmaceutical Industry, Biologics, Gene Therapy, Schizophrenia, Major Depressive Disorder, Epilepsy, Obesity, Orphan Drug, Intellectual Property, Healthcare Regulation, Financial Performance, Pipeline, Share Repurchase